Clinical Trial Update: Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2 [Phase 2]

View source ↗

Summary

Phase II trial of J591 monoclonal antibody in combination with low-dose subcutaneous interleukin-2 for prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Interleukin-2 (interleukin-2)
• J591 (PSMA-targeted monoclonal antibody)

Snippet

Sponsor: BZL Biologics | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED